KA/EN
Register
Medicines reference
Search
Search
Product

Ciflodex

Favourites

Ciprofloxacin + Dexamethasone · Brovapharma LLC

1 form: eye drops. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose a species; its rows are highlighted.
Form Species Dose Frequency Georgia
4.5/1 mg/ml eye and ear drops suspension, Eye drops · Cat Cat 1–2 drops
Shake before use and instil into the conjunctival sac. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Despite the exact page listing corneal ulcers and erosions, topical dexamethasone must not be used over an epithelial defect: perform fluorescein staining before treatment and at deterioration. Exclude viral/fungal disease, glaucoma and uncontrolled infection; in cats specifically assess FHV-1. The label prohibits NSAIDs, theophylline, amphotericin and literally states other calcium-depleting medicines; do not silently reinterpret this wording because no exact interaction study is supplied. Use cautiously below 7 days and in pregnancy; lactation safety is not stated.
 · 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only		 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only Georgia Yes, veterinary
In force until 06 Oct 2027
Veterinary (National Food Agency)
In the register: ციფლოდექსი — თვალისა და ყურის წვეთები
№ 000208
Verified on: 23 Oct 2026
4.5/1 mg/ml eye and ear drops suspension, Eye drops · Cat Cat 1–4 drops
Shake before use. Perform otoscopy and cytology before cleaning; instil 1-4 drops according to patient size, but the exact instruction gives no size bands. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Use only for a diagnosed susceptible bacterial/inflammatory external-ear role; it contains no antifungal. The exact instruction does not address tympanic-membrane integrity, otitis media/interna, hearing/vestibular safety or feline-specific outcome data, so do not use through a non-intact or unvisualised tympanum. Observe the exact viral/fungal, vaccination, age, pregnancy and interaction restrictions.
 · 1-4 drops by size q8-12h for 5-10 days		 1-4 drops by size q8-12h for 5-10 days Georgia Yes, veterinary
In force until 06 Oct 2027
Veterinary (National Food Agency)
In the register: ციფლოდექსი — თვალისა და ყურის წვეთები
№ 000208
Verified on: 23 Oct 2026
4.5/1 mg/ml eye and ear drops suspension, Eye drops · Dog Dog 1–2 drops
Shake before use and instil into the conjunctival sac. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Despite the exact page listing corneal ulcers and erosions, topical dexamethasone must not be used over an epithelial defect: perform fluorescein staining before treatment and at deterioration. Exclude viral/fungal disease, glaucoma and uncontrolled infection; in cats specifically assess FHV-1. The label prohibits NSAIDs, theophylline, amphotericin and literally states other calcium-depleting medicines; do not silently reinterpret this wording because no exact interaction study is supplied. Use cautiously below 7 days and in pregnancy; lactation safety is not stated.
 · 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only		 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only Georgia Yes, veterinary
In force until 06 Oct 2027
Veterinary (National Food Agency)
In the register: ციფლოდექსი — თვალისა და ყურის წვეთები
№ 000208
Verified on: 23 Oct 2026
4.5/1 mg/ml eye and ear drops suspension, Eye drops · Dog Dog 1–4 drops
Shake before use. Perform otoscopy and cytology before cleaning; instil 1-4 drops according to patient size, but the exact instruction gives no size bands. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Use only for a diagnosed susceptible bacterial/inflammatory external-ear role; it contains no antifungal. The exact instruction does not address tympanic-membrane integrity, otitis media/interna, hearing/vestibular safety or feline-specific outcome data, so do not use through a non-intact or unvisualised tympanum. Observe the exact viral/fungal, vaccination, age, pregnancy and interaction restrictions.
 · 1-4 drops by size q8-12h for 5-10 days		 1-4 drops by size q8-12h for 5-10 days Georgia Yes, veterinary
In force until 06 Oct 2027
Veterinary (National Food Agency)
In the register: ციფლოდექსი — თვალისა და ყურის წვეთები
№ 000208
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Ciflodex 4.5/1 mg/ml eye and ear drops suspension, Eye drops

10 ml for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete labelled dog/cat ophthalmic role: bacterial, chemical or traumatic conjunctival, eyelid, corneal, uveal, injury-related and perioperative disease, including ulcer/erosion claims, with modern corneal-safety boundaries
3.2/10
Poor / unconvincing
vetman assessment

Ciflodex

4.5/1 mg/ml eye and ear drops suspension, 10 ml for dogs and cats
Assessed clinical scopeDog · Complete labelled dog/cat ophthalmic role: bacterial, chemical or traumatic conjunctival, eyelid, corneal, uveal, injury-related and perioperative disease, including ulcer/erosion claims, with modern corneal-safety boundaries · Into the eye
Care settingVeterinarian-directed treatment only after complete ocular examination, fluorescein staining, infection assessment and IOP review where indicated, with early scheduled recheck
vetman score 3.2/10 Poor / unconvincing
Evidence confidence: Low Georgia: Yes, veterinary · № 000208 · Verified on 23 Oct 2026

A registered but poorly supported fixed eye combination whose broad label includes the very corneal ulcers/erosions that make topical dexamethasone dangerous. Ciprofloxacin may fit selected susceptible infections, but without an intact fluorescein-negative cornea, a diagnosis supporting both components and close recheck, this is a poor option rather than a general red-eye treatment.

Regulatory and scientific credibility4.5/10

Exact 10 ml identity, strengths, dog/cat routes, dose schedules and Georgian authorisation 000208 are current and traceable. However clinical detail is available only on a manufacturer sales page, no internationally recognised exact veterinary authorisation or assessment dossier was found, and the page's broad ulcer/trauma claims conflict with established ophthalmic corticosteroid safety.

Clinical efficacy3.0/10

Ciprofloxacin can cover selected susceptible ocular bacteria and dexamethasone can suppress steroid-responsive inflammation, but no exact-product outcome study supports this broad mixed-cause label. The fixed steroid is inappropriate for many infected/ulcerated eyes, and a direct canine in-vitro study found dexamethasone significantly increased ciprofloxacin resistance/MIC in S. pseudintermedius and P. aeruginosa isolates.

Safety and tolerability2.0/10

The exact page explicitly lists corneal ulcers/erosions despite dexamethasone delaying epithelial repair, promoting collagenolysis/melting and masking infection. It also acknowledges irritation, allergy, secondary glaucoma and steroid cataract; systemic absorption, pressure effects and steroid keratopathy are independently documented, while exact target-eye safety margins are absent.

Clinical practicality3.5/10

Ready-to-use drops and a 5-10-day course are familiar, but 2-4 daily doses—and every 2-3 hours in severe cases—create substantial home/clinic burden. Safe use also requires shaking, atraumatic restraint, fluorescein and infection assessment, tip hygiene, spacing other drops, early recheck and one-month open-bottle control.

Full-course cost-effectiveness-

Current Georgian price for the exact 10 ml bottle and complete route-specific course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete eye-label boundary: conjunctivitis, blepharitis, keratitis/keratoconjunctivitis, iritis/iridocyclitis, ulcer/erosion, trauma/foreign body/chemical and perioperative disease are listed. This does not make one fixed antibiotic-steroid appropriate for every cause; diagnose the compartment, epithelial integrity and microbial/inflammatory role first.
  • Shake and give 1-2 conjunctival drops 2-4 times daily for 5-10 days; severe cases may receive 1-2 drops every 2-3 hours only for the first 1-2 days. Heavy discharge: use the label's cleaning step, then administer the treatment dose. Reassess early rather than extending blindly.
  • Hard stop: perform fluorescein staining before the first dose and at any new pain or deterioration. Despite the exact label listing corneal ulcer/erosion, do not use topical dexamethasone over an epithelial defect, thinning, melting, descemetocele, perforation or unhealed penetrating injury.
  • Use ciprofloxacin only when a susceptible bacterial role is clinically justified; culture/susceptibility is important in ulcerative keratitis, deep infection, rods, recurrence, prior fluoroquinolone exposure or poor response. Dexamethasone can alter susceptibility and suppress visible inflammation without microbial cure.
  • Do not use for viral or fungal eye/ear disease or uncontrolled infection. Steroid-driven reduction in redness, pain or discharge does not establish eradication and can permit microbial overgrowth; stop and re-evaluate if response is incomplete or deterioration occurs.
  • Monitor for irritation, itching, tearing, allergy, delayed healing, infection, IOP rise, secondary glaucoma, steroid cataract and corneal opacity/keratopathy. New blepharospasm, clouding, staining, vision change or worsening discharge requires immediate cessation and examination.
  • The exact page prohibits concurrent NSAIDs, theophylline, amphotericin and literally “other calcium-depleting medicines,” and prohibits use during vaccination. No exact interaction study explains the calcium wording; document all systemic/topical medicines and seek source clarification rather than silently changing or ignoring it.
  • Use cautiously below 7 days of age and in pregnancy. The exact instruction does not establish lactation, breeding, liver/kidney disease, repeated-course or overdose safety; use the shortest justified course and a patient-specific benefit-risk decision.
  • Shake thoroughly, wash hands, use atraumatic restraint and keep the dropper tip sterile and away from eye, lashes, skin and fingers. Separate other eye medicines so one does not wash out another; ointment is generally placed last unless the ophthalmologist directs otherwise.
  • Store dry and dark at 10-25 C out of children's reach and discard one month after opening. Record opening date, route/eye/ear, dose, diagnosis, culture/cytology basis and recheck; never use one contaminated bottle interchangeably between eyes and ears.
Assessment sources
  1. Ciflodex GE register2026
  2. Brovapharma Ciflodex2026
  3. EU Ciflodex market audit2026
  4. GB Ciflodex market audit2026
  5. FDA Ciflodex market audit2026
  6. MSD ophthalmic steroids2026
  7. Merck ophthalmic antimicrobials2025
  8. Canine dexamethasone interaction2026
  9. Canine steroid keratopathy2024
  10. ABCD feline herpesvirus guideline2009
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Complete labelled dog/cat otic role: acute or chronic bacterial, chemical or traumatic external-ear inflammation, otitis and otorrhoea, including after intervention, only with an intact tympanum
4.2/10
Weak evidence support
vetman assessment

Ciflodex

4.5/1 mg/ml eye and ear drops suspension, 10 ml for dogs and cats
Assessed clinical scopeDog · Complete labelled dog/cat otic role: acute or chronic bacterial, chemical or traumatic external-ear inflammation, otitis and otorrhoea, including after intervention, only with an intact tympanum · Into the ear
Care settingVeterinarian-directed external-ear treatment after otoscopy, intact-tympanum confirmation and cytology before cleaning, with cause-directed care and clinical/cytologic recheck
vetman score 4.2/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000208 · Verified on 23 Oct 2026

A weak, selective dog otic option when cytology supports susceptible bacterial external otitis and the tympanum is intact. Plausible ingredients and a short course cannot replace the missing exact outcome/safety programme, antifungal gap, organism criteria or size bands.

Regulatory and scientific credibility4.5/10

Exact 10 ml identity, strengths, dog/cat routes, dose schedules and Georgian authorisation 000208 are current and traceable. However clinical detail is available only on a manufacturer sales page, no internationally recognised exact veterinary authorisation or assessment dossier was found, and the page's broad ulcer/trauma claims conflict with established ophthalmic corticosteroid safety.

Clinical efficacy4.0/10

Ciprofloxacin/dexamethasone has a credible otic formulation bridge and can plausibly help susceptible bacterial inflammatory otitis externa, but no exact dog outcome study, organism eligibility or numeric size bands were found. It lacks an antifungal, so it cannot cover the common mixed Malassezia role of authorised veterinary combinations or justify treatment of every chemically/traumatically inflamed ear.

Safety and tolerability4.0/10

Topical exposure is likely lower-risk than systemic fluoroquinolone/steroid use, and a human same-class otic comparator has controlled non-intact-ear data. But that human formulation cannot validate this veterinary suspension: the exact label omits tympanum status, otitis media/interna, auditory/vestibular outcomes, adverse-event frequencies and repeat-course safety.

Clinical practicality4.5/10

A 5-10-day ready-drop course is workable, but 2-3 daily administrations, cleaning, massage and complete restraint still matter. The 1-4-drop range lacks weight/size bands, and otoscopy, cytology, intact-tympanum confirmation and recheck add justified clinical work.

Full-course cost-effectiveness-

Current Georgian price for the exact 10 ml bottle and complete route-specific course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete ear-label boundary: acute/chronic bacterial, chemical or traumatic inflammation, otitis and otorrhoea are listed. This score covers only diagnosed external-ear disease with an intact tympanum, not otitis media/interna, undifferentiated discharge or every inflamed ear.
  • Shake and give 1-4 drops by patient size 2-3 times daily for 5-10 days after indicated cleaning; the exact label provides no size/weight bands. Document the selected volume, canal findings and response instead of treating 1-4 drops as interchangeable.
  • Hard stop: perform otoscopy and confirm an intact tympanic membrane before use. The exact label gives no perforation or middle-ear safety data; do not transfer human CIPRODEX tympanostomy evidence to this veterinary formulation or use in an unvisualised/non-intact ear.
  • Obtain cytology before cleaning in every otitis case; culture/susceptibility is important with rods, chronic/recurrent disease, prior fluoroquinolone exposure or poor response. It has no antifungal, so yeast or mixed infection needs a different cause-directed plan.
  • Do not use for viral or fungal eye/ear disease or uncontrolled infection. Steroid-driven reduction in redness, pain or discharge does not establish eradication and can permit microbial overgrowth; stop and re-evaluate if response is incomplete or deterioration occurs.
  • Stop for marked irritation, swelling, worsening discharge/pain, head tilt, nystagmus, ataxia, facial/Horner signs or hearing change. Investigate contact reaction, resistant infection, foreign body, mass/polyp and middle/inner-ear disease rather than layering more drops.
  • The exact page prohibits concurrent NSAIDs, theophylline, amphotericin and literally “other calcium-depleting medicines,” and prohibits use during vaccination. No exact interaction study explains the calcium wording; document all systemic/topical medicines and seek source clarification rather than silently changing or ignoring it.
  • Use cautiously below 7 days of age and in pregnancy. The exact instruction does not establish lactation, breeding, liver/kidney disease, repeated-course or overdose safety; use the shortest justified course and a patient-specific benefit-risk decision.
  • Shake thoroughly, clean as directed, use safe restraint and prevent tip contact with canal, pinna, skin or fingers. Massage only when comfortable and the tympanum is intact; prevent licking and cross-use between infected ears/animals.
  • Store dry and dark at 10-25 C out of children's reach and discard one month after opening. Record opening date, route/eye/ear, dose, diagnosis, culture/cytology basis and recheck; never use one contaminated bottle interchangeably between eyes and ears.
Assessment sources
  1. Ciflodex GE register2026
  2. Brovapharma Ciflodex2026
  3. EU Ciflodex market audit2026
  4. GB Ciflodex market audit2026
  5. FDA Ciflodex market audit2026
  6. MSD otitis externa2026
  7. AAHA otitis 20232023
  8. CIPRODEX otic comparator2026
  9. FDA otic evidence control2015
  10. Ototop EU identity2026
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete labelled dog/cat ophthalmic role: bacterial, chemical or traumatic conjunctival, eyelid, corneal, uveal, injury-related and perioperative disease, including ulcer/erosion claims, with modern corneal-safety boundaries
2.9/10
Poor / unconvincing
vetman assessment

Ciflodex

4.5/1 mg/ml eye and ear drops suspension, 10 ml for dogs and cats
Assessed clinical scopeCat · Complete labelled dog/cat ophthalmic role: bacterial, chemical or traumatic conjunctival, eyelid, corneal, uveal, injury-related and perioperative disease, including ulcer/erosion claims, with modern corneal-safety boundaries · Into the eye
Care settingVeterinarian-directed treatment only after complete ocular examination, fluorescein staining, infection assessment and IOP review where indicated, with early scheduled recheck
vetman score 2.9/10 Poor / unconvincing
Evidence confidence: Low Georgia: Yes, veterinary · № 000208 · Verified on 23 Oct 2026

A poor feline eye option: exact efficacy is absent, common FHV-associated disease can be worsened by steroid exposure, and the label's ulcer claim conflicts with a hard corneal-safety boundary. It should never be used empirically for a red or painful cat eye.

Regulatory and scientific credibility4.5/10

Exact 10 ml identity, strengths, dog/cat routes, dose schedules and Georgian authorisation 000208 are current and traceable. However clinical detail is available only on a manufacturer sales page, no internationally recognised exact veterinary authorisation or assessment dossier was found, and the page's broad ulcer/trauma claims conflict with established ophthalmic corticosteroid safety.

Clinical efficacy2.5/10

No exact-product feline outcome study was found. Ciprofloxacin activity and dexamethasone anti-inflammatory action are plausible only after diagnosis, while viral disease—especially FHV-associated conjunctivitis/keratitis—is common and specifically makes the fixed steroid problematic; canine in-vitro findings and human combinations are indirect, not feline efficacy.

Safety and tolerability1.5/10

All corneal healing, infection, glaucoma and cataract hazards apply, plus topical corticosteroids can reactivate feline herpesvirus and precipitate ulcerative keratitis or sequestrum. An exact label that simultaneously excludes viral disease yet broadly includes ulcers without requiring fluorescein testing creates a particularly poor feline safety fit; controlled exact feline safety is absent.

Clinical practicality3.5/10

Ready-to-use drops and a 5-10-day course are familiar, but 2-4 daily doses—and every 2-3 hours in severe cases—create substantial home/clinic burden. Safe use also requires shaking, atraumatic restraint, fluorescein and infection assessment, tip hygiene, spacing other drops, early recheck and one-month open-bottle control.

Full-course cost-effectiveness-

Current Georgian price for the exact 10 ml bottle and complete route-specific course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete eye-label boundary: conjunctivitis, blepharitis, keratitis/keratoconjunctivitis, iritis/iridocyclitis, ulcer/erosion, trauma/foreign body/chemical and perioperative disease are listed. This does not make one fixed antibiotic-steroid appropriate for every cause; diagnose the compartment, epithelial integrity and microbial/inflammatory role first.
  • Shake and give 1-2 conjunctival drops 2-4 times daily for 5-10 days; severe cases may receive 1-2 drops every 2-3 hours only for the first 1-2 days. Heavy discharge: use the label's cleaning step, then administer the treatment dose. Reassess early rather than extending blindly.
  • Hard stop: perform fluorescein staining before the first dose and at any new pain or deterioration. Despite the exact label listing corneal ulcer/erosion, do not use topical dexamethasone over an epithelial defect, thinning, melting, descemetocele, perforation or unhealed penetrating injury.
  • Use ciprofloxacin only when a susceptible bacterial role is clinically justified; culture/susceptibility is important in ulcerative keratitis, deep infection, rods, recurrence, prior fluoroquinolone exposure or poor response. Dexamethasone can alter susceptibility and suppress visible inflammation without microbial cure.
  • Do not use for suspected FHV-1 or other viral/fungal ocular disease. Topical corticosteroids can reactivate feline herpesvirus and precipitate ulcerative keratitis or corneal sequestrum; investigate dendritic/geographic lesions and treat the cause before any further immunosuppression.
  • Monitor for irritation, itching, tearing, allergy, delayed healing, infection, IOP rise, secondary glaucoma, steroid cataract and corneal opacity/keratopathy. New blepharospasm, clouding, staining, vision change or worsening discharge requires immediate cessation and examination.
  • The exact page prohibits concurrent NSAIDs, theophylline, amphotericin and literally “other calcium-depleting medicines,” and prohibits use during vaccination. No exact interaction study explains the calcium wording; document all systemic/topical medicines and seek source clarification rather than silently changing or ignoring it.
  • Use cautiously below 7 days of age and in pregnancy. The exact instruction does not establish lactation, breeding, liver/kidney disease, repeated-course or overdose safety; use the shortest justified course and a patient-specific benefit-risk decision.
  • Shake thoroughly, wash hands, use atraumatic restraint and keep the dropper tip sterile and away from eye, lashes, skin and fingers. Separate other eye medicines so one does not wash out another; ointment is generally placed last unless the ophthalmologist directs otherwise.
  • Store dry and dark at 10-25 C out of children's reach and discard one month after opening. Record opening date, route/eye/ear, dose, diagnosis, culture/cytology basis and recheck; never use one contaminated bottle interchangeably between eyes and ears.
Assessment sources
  1. Ciflodex GE register2026
  2. Brovapharma Ciflodex2026
  3. EU Ciflodex market audit2026
  4. GB Ciflodex market audit2026
  5. FDA Ciflodex market audit2026
  6. MSD ophthalmic steroids2026
  7. Merck ophthalmic antimicrobials2025
  8. Canine dexamethasone interaction2026
  9. Canine steroid keratopathy2024
  10. ABCD feline herpesvirus guideline2009
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete labelled dog/cat otic role: acute or chronic bacterial, chemical or traumatic external-ear inflammation, otitis and otorrhoea, including after intervention, only with an intact tympanum
4.0/10
Weak evidence support
vetman assessment

Ciflodex

4.5/1 mg/ml eye and ear drops suspension, 10 ml for dogs and cats
Assessed clinical scopeCat · Complete labelled dog/cat otic role: acute or chronic bacterial, chemical or traumatic external-ear inflammation, otitis and otorrhoea, including after intervention, only with an intact tympanum · Into the ear
Care settingVeterinarian-directed external-ear treatment after otoscopy, intact-tympanum confirmation and cytology before cleaning, with cause-directed care and clinical/cytologic recheck
vetman score 4.0/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000208 · Verified on 23 Oct 2026

A weak feline otic option with plausible local activity but no exact feline outcomes, antifungal coverage, tympanic safety programme or objective drop bands. Use only after diagnosis, intact-tympanum confirmation and planned recheck—not for every inflamed or discharging ear.

Regulatory and scientific credibility4.5/10

Exact 10 ml identity, strengths, dog/cat routes, dose schedules and Georgian authorisation 000208 are current and traceable. However clinical detail is available only on a manufacturer sales page, no internationally recognised exact veterinary authorisation or assessment dossier was found, and the page's broad ulcer/trauma claims conflict with established ophthalmic corticosteroid safety.

Clinical efficacy3.5/10

The same antibacterial/anti-inflammatory rationale is plausible, but no exact feline outcome or target-organism study was found and direct feline otitis evidence is sparse. The broad otitis/otorrhoea label supplies neither cytology criteria nor antifungal activity, so dog, human and other veterinary combinations provide only indirect support.

Safety and tolerability4.0/10

The main local and tympanic uncertainties apply, while no exact feline canal, hearing or vestibular safety study was found. Cats can be difficult to examine and restrain, and an unrecognised polyp/middle-ear process or contact reaction can be masked by steroid relief; exact adverse-event denominators and repeat-course data are absent.

Clinical practicality4.0/10

The small ready-drop volume is feasible, but many cats resist repeated ear handling 2-3 times daily for 5-10 days. The unbanded 1-4-drop range, safe restraint, cleaning, otoscopy/cytology, intact-tympanum confirmation, tip hygiene and recheck create a meaningful welfare/adherence burden.

Full-course cost-effectiveness-

Current Georgian price for the exact 10 ml bottle and complete route-specific course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete ear-label boundary: acute/chronic bacterial, chemical or traumatic inflammation, otitis and otorrhoea are listed. This score covers only diagnosed external-ear disease with an intact tympanum, not otitis media/interna, undifferentiated discharge or every inflamed ear.
  • Shake and give 1-4 drops by patient size 2-3 times daily for 5-10 days after indicated cleaning; the exact label provides no size/weight bands. Document the selected volume, canal findings and response instead of treating 1-4 drops as interchangeable.
  • Hard stop: perform otoscopy and confirm an intact tympanic membrane before use. The exact label gives no perforation or middle-ear safety data; do not transfer human CIPRODEX tympanostomy evidence to this veterinary formulation or use in an unvisualised/non-intact ear.
  • Obtain cytology before cleaning in every otitis case; culture/susceptibility is important with rods, chronic/recurrent disease, prior fluoroquinolone exposure or poor response. It has no antifungal, so yeast or mixed infection needs a different cause-directed plan.
  • Do not use for viral or fungal eye/ear disease or uncontrolled infection. Steroid-driven reduction in redness, pain or discharge does not establish eradication and can permit microbial overgrowth; stop and re-evaluate if response is incomplete or deterioration occurs.
  • Stop for marked irritation, swelling, worsening discharge/pain, head tilt, nystagmus, ataxia, facial/Horner signs or hearing change. Investigate contact reaction, resistant infection, foreign body, mass/polyp and middle/inner-ear disease rather than layering more drops.
  • The exact page prohibits concurrent NSAIDs, theophylline, amphotericin and literally “other calcium-depleting medicines,” and prohibits use during vaccination. No exact interaction study explains the calcium wording; document all systemic/topical medicines and seek source clarification rather than silently changing or ignoring it.
  • Use cautiously below 7 days of age and in pregnancy. The exact instruction does not establish lactation, breeding, liver/kidney disease, repeated-course or overdose safety; use the shortest justified course and a patient-specific benefit-risk decision.
  • Shake thoroughly, clean as directed, use safe restraint and prevent tip contact with canal, pinna, skin or fingers. Massage only when comfortable and the tympanum is intact; prevent licking and cross-use between infected ears/animals.
  • Store dry and dark at 10-25 C out of children's reach and discard one month after opening. Record opening date, route/eye/ear, dose, diagnosis, culture/cytology basis and recheck; never use one contaminated bottle interchangeably between eyes and ears.
Assessment sources
  1. Ciflodex GE register2026
  2. Brovapharma Ciflodex2026
  3. EU Ciflodex market audit2026
  4. GB Ciflodex market audit2026
  5. FDA Ciflodex market audit2026
  6. MSD otitis externa2026
  7. AAHA otitis 20232023
  8. CIPRODEX otic comparator2026
  9. FDA otic evidence control2015
  10. Ototop EU identity2026
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin4.5 mg/ml Dexamethasone1 mg/ml
Formulation Type
Eye drops
Administration route
Into the eye, Into the ear
Manufacturer
Brovapharma LLC · Ukraine
Manufacturer (register)
Brovapharma Ltd, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 746, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 06 Oct 2027
Veterinary (National Food Agency)
In the register: ციფლოდექსი — თვალისა და ყურის წვეთები
№ 000208
Verified on: 23 Oct 2026
 EU No
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Shake before every use. Eye: 1-2 drops into the conjunctival sac 2-4 times daily for 5-10 days; in severe cases every 2-3 hours only during the first 1-2 days, with prompt examination and reassessment. Ear: after otoscopy, cytology and appropriate cleaning, 1-4 drops according to patient size 2-3 times daily for 5-10 days; the label supplies no size bands. For heavy discharge the label uses 3-4 drops for cleaning with sterile gauze, followed by 1-2 treatment drops. Avoid dropper contact and discard one month after opening.
DoseSpeciesWeightRouteFrequencySource
1–2 drops
Shake before use and instil into the conjunctival sac. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Despite the exact page listing corneal ulcers and erosions, topical dexamethasone must not be used over an epithelial defect: perform fluorescein staining before treatment and at deterioration. Exclude viral/fungal disease, glaucoma and uncontrolled infection; in cats specifically assess FHV-1. The label prohibits NSAIDs, theophylline, amphotericin and literally states other calcium-depleting medicines; do not silently reinterpret this wording because no exact interaction study is supplied. Use cautiously below 7 days and in pregnancy; lactation safety is not stated.
 Cat Any weight Into the eye 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only
Brovapharma Ciflodex
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Ciflodex eye and ear drops - official manufacturer instruction
Brovapharma official product information, 2026
1–4 drops
Shake before use. Perform otoscopy and cytology before cleaning; instil 1-4 drops according to patient size, but the exact instruction gives no size bands. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Use only for a diagnosed susceptible bacterial/inflammatory external-ear role; it contains no antifungal. The exact instruction does not address tympanic-membrane integrity, otitis media/interna, hearing/vestibular safety or feline-specific outcome data, so do not use through a non-intact or unvisualised tympanum. Observe the exact viral/fungal, vaccination, age, pregnancy and interaction restrictions.
 Cat Any weight Into the ear 1-4 drops by size q8-12h for 5-10 days
Brovapharma Ciflodex
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Ciflodex eye and ear drops - official manufacturer instruction
Brovapharma official product information, 2026
1–2 drops
Shake before use and instil into the conjunctival sac. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Despite the exact page listing corneal ulcers and erosions, topical dexamethasone must not be used over an epithelial defect: perform fluorescein staining before treatment and at deterioration. Exclude viral/fungal disease, glaucoma and uncontrolled infection; in cats specifically assess FHV-1. The label prohibits NSAIDs, theophylline, amphotericin and literally states other calcium-depleting medicines; do not silently reinterpret this wording because no exact interaction study is supplied. Use cautiously below 7 days and in pregnancy; lactation safety is not stated.
 Dog Any weight Into the eye 1-2 drops q6-12h for 5-10 days; severe q2-3h for first 1-2 days only
Brovapharma Ciflodex
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Ciflodex eye and ear drops - official manufacturer instruction
Brovapharma official product information, 2026
1–4 drops
Shake before use. Perform otoscopy and cytology before cleaning; instil 1-4 drops according to patient size, but the exact instruction gives no size bands. If discharge is heavy, the label says to use 3-4 drops for cleaning with sterile gauze, then administer 1-2 treatment drops. Use only for a diagnosed susceptible bacterial/inflammatory external-ear role; it contains no antifungal. The exact instruction does not address tympanic-membrane integrity, otitis media/interna, hearing/vestibular safety or feline-specific outcome data, so do not use through a non-intact or unvisualised tympanum. Observe the exact viral/fungal, vaccination, age, pregnancy and interaction restrictions.
 Dog Any weight Into the ear 1-4 drops by size q8-12h for 5-10 days
Brovapharma Ciflodex
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Ciflodex eye and ear drops - official manufacturer instruction
Brovapharma official product information, 2026
Active substance doses, with sources
Active substance Ciprofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25–50 mg/kg
off-label
 Dog Bacterial Infection
adults
 By mouth once daily
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Quinolones, Including Fluoroquinolones, for Use in Animals
MSD/Merck Veterinary Manual, 2026
Active substance Dexamethasone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.05–0.2 mg/kg Dog Inflammation By mouth once daily in the morning
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.1 mg/kg Dog, Cat Allergic Reaction Intramuscular as needed
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexadreson 2 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.05–0.2 mg/kg Cat Inflammation By mouth once daily in the evening
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical Ciprofloxacin
    Do not use ciprofloxacin in patients with known hypersensitivity to ciprofloxacin or another fluoroquinolone.
  • Warning Ciprofloxacin
    Both ciprofloxacin and moxifloxacin have been associated with potentially fatal antimicrobial-induced colitis.
    Sources: MSD Vet Manual
  • Warning Ciprofloxacin
    Avoid excessive or prolonged quinolone use in immature animals because cartilage erosion and permanent lameness have occurred in growing dogs and foals.
    Sources: MSD Vet Manual
  • Warning Ciprofloxacin (Cat)
    Not well absorbed in cats
    Sources: MSD Vet Manual
  • Critical Dexamethasone
    Do not use corticosteroids, topically or systemically, while a corneal ulcer is present. They slow healing of the corneal epithelium and can increase collagenase activity, which may turn the ulcer into a melting ulcer.
    Sources: MSD Vet Manual
  • Critical Dexamethasone
    Do not use dexamethasone in animals with diabetes mellitus or hyperadrenocorticism unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use in animals with diabetes mellitus or hyperadrenocorticism.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use dexamethasone in animals with osteoporosis because corticosteroids increase protein catabolism and can reduce bone mass.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use dexamethasone in animals with cardiac or renal dysfunction, including congestive heart failure, unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use in animals with cardiac or renal dysfunction.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use in animals with gastro-intestinal ulceration.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use dexamethasone in animals with glaucoma.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use systemic dexamethasone in animals with burns unless specifically indicated and closely monitored.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use dexamethasone during pregnancy because early exposure can cause fetal abnormalities and late exposure can induce abortion or premature parturition.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Known hypersensitivity to dexamethasone, another corticosteroid, or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical Dexamethasone
    Do not use in animals with viral or mycotic infections.
    Sources: VMD SPC · VMD
  • Warning Dexamethasone
    Use with particular caution in an immunocompromised patient because corticosteroids delay wound healing and can exacerbate an existing infection.
    Sources: VMD SPC · VMD
  • Warning Dexamethasone
    Corticoids such as dexamethasone should be used with caution in patients with hypertension.
    Sources: VMD SPC · VMD
  • Warning Dexamethasone
    Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Warning Dexamethasone
    Do not use concomitantly with attenuated alive vaccine dexamethasone should not be used in combination with vaccines or within two weeks after vaccination
    Sources: VMD SPC · VMD
  • Caution Dexamethasone
    Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover.
    Sources: VMD SPC · VMD
  • Caution Dexamethasone
    Use cautiously in geriatric or debilitated animals because corticosteroids increase protein catabolism. Prolonged treatment can cause cushingoid changes, including fat redistribution, muscle weakness and atrophy, and osteoporosis.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Robenacoxib + Dexamethasone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Ciprofloxacin + Aminophylline
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce the aminophylline dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Theophylline + Ciprofloxacin
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce its dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Dexamethasone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Dexamethasone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Dexamethasone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Furosemide + Dexamethasone
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.
    Sources: VMD SPC · VMD
  • Minor warning Dexamethasone + Torasemide
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (91 more) Hide additional products

Same therapeutic group 91

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗